US FDA 510(k) Cleared

AI-Powered Precision Neuroimaging

Automated brain volumetry and neurotrauma decision-support tools trusted by 220+ clinical sites worldwide. Affordable, accessible, and built for precision medicine.

NeuroShield Brain Segmentation — Axial, Sagittal, Coronal Views
Live Brain Segmentation
0.91 Dice Accuracy FDA Validated

220+

Clinical Sites Worldwide

280

Subject US Validation Trial

0.91

Dice Coefficient Accuracy

510(k)

US FDA Cleared

End-to-End Neuroimaging Intelligence

From automated brain MR volumetry to CT-based neurotrauma triage — a comprehensive platform for neurologists, neuroradiologists, and neurosurgeons.

Neurotrauma

NeuroShield™ CT TBI

AI-based neurotrauma screening and quantification tool for Traumatic Brain Injury. Automates stroke lesion segmentation and midline shift detection, supporting rapid clinical decision-making in critical care.

Midline Shift Lesion Segmentation Rapid Triage CT Analysis

NeuroFlo™

Neurology workflow software that streamlines clinical operations — from scan intake to report delivery. Reduces radiologist burden through intelligent automation and centralized data visualization.

Workflow Optimization Dashboard Analytics Report Automation

VivoShield™ Sports

Sports-specific whole-body MRI assessment providing tissue distribution profiling, body mass analysis, and athletic wellness evaluation. Built for elite sports performance and injury prevention.

Whole Body MRI Tissue Profiling Athletic Wellness

See NeuroShield at Work

From worklist management to fully automated volumetric reports — a complete clinical decision-support workflow.

NeuroShield Volumetric Analysis Dashboard — Worklist with patient studies, scan statuses, and site management

Clinical Worklist Dashboard

Centralized scan management across all sites. Upload studies, track processing status, filter by site, status, and demographics — all in real time.

NeuroShield Volumetric Analysis Report — Brain structure volumes with reference ranges

Automated Volumetric Report (NVA)

Comprehensive brain structure analysis with absolute volumes, ICV percentages, and age/gender/ethnicity-adjusted reference ranges across 30+ structures.

3D Brain Segmentation Visualization — Axial, Sagittal, Coronal Views

3D Brain Segmentation Viewer

Color-coded segmentation overlay across axial, sagittal, and coronal planes. Interactive viewer with zoom, pan, and region-level inspection.

FDA 510(k) Cleared Technology

NeuroShield has been rigorously validated and cleared by the US FDA as a clinical decision-support tool for neurologists and neuroradiologists.

US FDA 510(k) Cleared K220034

Clinical Decision Support Tool for Neurologists & Neuroradiologists

  • 280-Subject US Clinical Validation

    Demonstrated high accuracy across scanner strengths, demographic subgroups, age ranges, and geographic regions.

  • Multi-Scanner Compatibility

    Validated across 1.5T and 3T scanners from multiple manufacturers. Scanner-agnostic architecture.

  • STAPLE-Validated Ground Truth

    Ground truth established by 3 US Board-Certified Radiologists using the STAPLE consensus algorithm.

  • Ethnicity-Specific Reference Ranges

    World's first volumetric tool with ranges adjusted to age, gender, and ethnicity for equitable precision medicine.

Precision Health for Everyone, Everywhere

InMed Prognostics Inc. is a pioneer in AI-driven predictive analytics, leveraging multi-modal data — including text, signal, and image — to build fully automated, organ-agnostic imaging platforms (US Patent No. 11263749).

Founded by Dr. Latha Poonamallee, InMed operates across India, Africa, and the Middle East, with deep expertise in developing and deploying automated image processing algorithms and AI/ML pipelines at clinical scale.

The company is expanding its product portfolio into CT Brain applications, Whole Body MRI wellness and athletic solutions, and lesion detection for pancreatic and liver cancer.

We believe that investing in healthcare is investing in our collective human future and that technology is a great lever to move towards precision health to extend quality of life. — Dr. Latha Poonamallee, Founder & CEO

Platform Capabilities

AI/Deep Net/3D Convolutional Networks
Automated Brain Segmentation
Cloud-Based Image Processing
Remote Site Monitoring
Dynamic Dashboards & Visualization
Clinical Trial Imaging Support
Multi-Modal Data Integration
Organ-Agnostic Architecture

Leadership

Dr. Latha Poonamallee — Founder & CEO, InMed AI
Dr. Latha Poonamallee
Founder & CEO

Ph.D., Case Western Reserve University, Cleveland, Ohio. Pioneer in AI-driven predictive analytics and precision medicine. Leading InMed's mission to bring affordable, accessible healthcare tools to everyone, everywhere.

Rajesh Kumar Purushottam — Co-Founder & CEO, InMed AI
Rajesh Kumar Purushottam
Co-Founder & CEO

Ph.D., Stanford University. Deep expertise in building and deploying fully automated image processing algorithms, AI/ML pipelines, and scalable cloud platforms for clinical-grade medical imaging.

Ready to Transform Your Neuroimaging Workflow?

Request a demo, start a 30-day free trial, or speak with our clinical solutions team.

Sales & Demos

sales@inmed.ai

Office

6th Floor, Awfis Kode 2,
Baner Pashan Link Road, Baner,
Pune, Maharashtra, India

Registered Office

Golden Galaxy, Pashan,
Pune, Maharashtra, India

Global Presence

India • Africa • Middle East • USA

Media & Partnerships

doc@inmed.ai

Request a Demo

Intended Use Disclaimer: NeuroShield is intended as a clinical decision-support tool to assist qualified healthcare professionals. It is not intended to replace clinical judgment, provide a definitive diagnosis, or be used as the sole basis for clinical decisions. NeuroShield MR Volumetry is US FDA 510(k) cleared (K220034). Product availability may vary by region and regulatory status. All claims regarding product performance refer to data obtained during controlled clinical validation studies. For full prescribing information and indications for use, contact InMed.AI.